HRP960345A2 - Use of ipriflavone to reduce the number of cd8+ cells - Google Patents
Use of ipriflavone to reduce the number of cd8+ cells Download PDFInfo
- Publication number
- HRP960345A2 HRP960345A2 HRP9502198A HRP960345A HRP960345A2 HR P960345 A2 HRP960345 A2 HR P960345A2 HR P9502198 A HRP9502198 A HR P9502198A HR P960345 A HRP960345 A HR P960345A HR P960345 A2 HRP960345 A2 HR P960345A2
- Authority
- HR
- Croatia
- Prior art keywords
- cells
- lymphocytes
- cytotoxic
- ipriflavone
- reaction
- Prior art date
Links
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 title claims description 13
- 229960005431 ipriflavone Drugs 0.000 title claims description 12
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- -1 infusion Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 19
- 231100000433 cytotoxic Toxicity 0.000 description 15
- 230000001472 cytotoxic effect Effects 0.000 description 15
- 230000008105 immune reaction Effects 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012645 endogenous antigen Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9502198A HU9502198D0 (en) | 1995-07-21 | 1995-07-21 | Novel indication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP960345A2 true HRP960345A2 (en) | 1998-02-28 |
Family
ID=10987063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP9502198A HRP960345A2 (en) | 1995-07-21 | 1996-07-18 | Use of ipriflavone to reduce the number of cd8+ cells |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0841915A1 (hu) |
| JP (1) | JP2001503371A (hu) |
| KR (1) | KR19990028933A (hu) |
| CN (1) | CN1191483A (hu) |
| AR (1) | AR002905A1 (hu) |
| AU (1) | AU6367096A (hu) |
| BG (1) | BG102182A (hu) |
| BR (1) | BR9610187A (hu) |
| CA (1) | CA2227421A1 (hu) |
| CZ (1) | CZ2798A3 (hu) |
| EA (1) | EA199800146A1 (hu) |
| EE (1) | EE9800020A (hu) |
| HR (1) | HRP960345A2 (hu) |
| HU (1) | HU9502198D0 (hu) |
| IL (1) | IL122751A0 (hu) |
| MX (1) | MX9800603A (hu) |
| NO (1) | NO980127L (hu) |
| PL (1) | PL324460A1 (hu) |
| SK (1) | SK3298A3 (hu) |
| WO (1) | WO1997003664A1 (hu) |
| YU (1) | YU42796A (hu) |
| ZA (1) | ZA966079B (hu) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1241079B (it) * | 1990-03-23 | 1993-12-29 | Chiesi Farma Spa | Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico |
| HU212932B (en) * | 1993-08-02 | 1996-12-30 | Chinoin Gyogyszer Es Vegyeszet | Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition |
-
1995
- 1995-07-21 HU HU9502198A patent/HU9502198D0/hu unknown
-
1996
- 1996-07-16 EE EE9800020A patent/EE9800020A/xx unknown
- 1996-07-16 EA EA199800146A patent/EA199800146A1/ru unknown
- 1996-07-16 CZ CZ9827A patent/CZ2798A3/cs unknown
- 1996-07-16 CN CN96195722A patent/CN1191483A/zh active Pending
- 1996-07-16 MX MX9800603A patent/MX9800603A/es unknown
- 1996-07-16 CA CA002227421A patent/CA2227421A1/en not_active Abandoned
- 1996-07-16 IL IL12275196A patent/IL122751A0/xx unknown
- 1996-07-16 BR BR9610187A patent/BR9610187A/pt not_active Application Discontinuation
- 1996-07-16 WO PCT/HU1996/000038 patent/WO1997003664A1/en not_active Application Discontinuation
- 1996-07-16 KR KR1019980700235A patent/KR19990028933A/ko not_active Application Discontinuation
- 1996-07-16 PL PL96324460A patent/PL324460A1/xx unknown
- 1996-07-16 JP JP50646497A patent/JP2001503371A/ja active Pending
- 1996-07-16 AU AU63670/96A patent/AU6367096A/en not_active Abandoned
- 1996-07-16 SK SK32-98A patent/SK3298A3/sk unknown
- 1996-07-16 EP EP96923004A patent/EP0841915A1/en not_active Withdrawn
- 1996-07-17 ZA ZA9606079A patent/ZA966079B/xx unknown
- 1996-07-18 HR HRP9502198A patent/HRP960345A2/hr not_active Application Discontinuation
- 1996-07-19 YU YU42796A patent/YU42796A/sh unknown
- 1996-07-22 AR ARP960103677A patent/AR002905A1/es unknown
-
1998
- 1998-01-12 NO NO980127A patent/NO980127L/no unknown
- 1998-01-14 BG BG102182A patent/BG102182A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL122751A0 (en) | 1998-08-16 |
| EE9800020A (et) | 1998-08-17 |
| BG102182A (en) | 1998-08-31 |
| NO980127D0 (no) | 1998-01-12 |
| EP0841915A1 (en) | 1998-05-20 |
| HU9502198D0 (en) | 1995-09-28 |
| PL324460A1 (en) | 1998-05-25 |
| CZ2798A3 (cs) | 1998-06-17 |
| MX9800603A (es) | 1998-04-30 |
| KR19990028933A (ko) | 1999-04-15 |
| AR002905A1 (es) | 1998-04-29 |
| SK3298A3 (en) | 1998-07-08 |
| JP2001503371A (ja) | 2001-03-13 |
| NO980127L (no) | 1998-01-12 |
| EA199800146A1 (ru) | 1998-08-27 |
| CN1191483A (zh) | 1998-08-26 |
| YU42796A (sh) | 1999-03-04 |
| WO1997003664A8 (en) | 1999-08-05 |
| WO1997003664A1 (en) | 1997-02-06 |
| AU6367096A (en) | 1997-02-18 |
| CA2227421A1 (en) | 1997-02-06 |
| ZA966079B (en) | 1998-01-19 |
| BR9610187A (pt) | 1998-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3010310B2 (ja) | アイコサペンタエノン酸の悪液質治療への利用 | |
| EP2167099B1 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
| JP2012255020A (ja) | ジアルキルフマレート含有薬剤調合物 | |
| KR100479968B1 (ko) | 위장 리파아제 억제제의 용도 | |
| KR100424503B1 (ko) | 암전이억제제 | |
| WO1993024144A1 (en) | PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY | |
| KR950008767B1 (ko) | 에브셀렌(Ebselen)의 새로운 의약적 용도 | |
| CN100571776C (zh) | Ppar配体和抗氧剂间的联合及其用于治疗肥胖的用途 | |
| WO1993017691A2 (en) | Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease | |
| JPS6379824A (ja) | 制癌剤 | |
| HRP960345A2 (en) | Use of ipriflavone to reduce the number of cd8+ cells | |
| WO2001049269A1 (en) | Sustained-releasing anthelmintic compositions comprising praziquantel | |
| JPH0686377B2 (ja) | がん転移抑制剤 | |
| JPH06135836A (ja) | コントラサプレッサー細胞の誘導剤 | |
| US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
| US5571800A (en) | Method for inhibiting allograft rejection by the administration of 6-azauridine or its triacetate derivative | |
| EP0005074A1 (en) | A material and composition for reducing blood pressure | |
| US3666861A (en) | Methods for treating migraine which use 2-(2{40 ,6{40 -dichlorophenyl-amino)-1,3-diszacyclopentene-(2) | |
| MXPA98000603A (en) | Use of ipriflavona to reduce the number of cells c | |
| CA2193838A1 (en) | Disease preventive/remedy | |
| CN118045071A (zh) | 一种治疗缺血性脑卒中疾病的联合用药物及其应用 | |
| CA2013443A1 (en) | Pharmaceutical compositions and their use in the treatment of parasitoses | |
| CN112370486A (zh) | 一种藏药十三味红花丸组合物及其制备方法与应用 | |
| AU672610C (en) | Preparation for activation of natural killer cells (NK-cells), said preparation containing interferon-alpha and histamine, serotonin or substances with corresponding receptor activity | |
| KR20090059017A (ko) | 간질환치료 및 간기능개선용 약학조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| OBST | Application withdrawn |